Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.7%

119 terminated/withdrawn out of 2094 trials

Success Rate

91.0%

+4.5% vs industry average

Late-Stage Pipeline

4%

92 trials in Phase 3/4

Results Transparency

36%

430 of 1210 completed trials have results

Key Signals

337 recruiting430 with results78 terminated41 withdrawn

Enrollment Performance

Analytics

Phase 2
675(41.8%)
Phase 1
471(29.1%)
N/A
338(20.9%)
Phase 3
82(5.1%)
Early Phase 1
40(2.5%)
Phase 4
10(0.6%)
1616Total
Phase 2(675)
Phase 1(471)
N/A(338)
Phase 3(82)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2094)

Showing 20 of 2094 trials
NCT06957314Not ApplicableRecruiting

A Study of Hospital-at-Home for People Receiving Tarlatamab

Role: lead

NCT01430390Phase 1Active Not Recruiting

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Role: lead

NCT01742143Recruiting

Impact of ICCAN on Cancer Treatment Completion and Quality of Life

Role: lead

NCT04960618Phase 2Active Not Recruiting

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Role: lead

NCT03572374Not ApplicableRecruiting

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

Role: lead

NCT07223021Phase 3Recruiting

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Role: lead

NCT00597636Active Not Recruiting

Genetic Susceptibility to Lung Cancer in Never Smokers

Role: lead

NCT07082868Phase 1Recruiting

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Role: lead

NCT07619339Phase 1Recruiting

A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

Role: lead

NCT06457919Phase 1Recruiting

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Role: lead

NCT07638371Phase 1Recruiting

A Study of MSK-TCR5 in People With Solid Tumor Cancers

Role: lead

NCT05419076Phase 2Recruiting

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Role: lead

NCT04167969Phase 1Recruiting

The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer

Role: lead

NCT07209449Phase 2Recruiting

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Role: lead

NCT04802720Not ApplicableActive Not Recruiting

A Study Comparing Two Types of Supportive Interventions for Caregivers of Patients With Cancer

Role: lead

NCT07335354Not ApplicableRecruiting

A Study of a Decision Tool for People Considering Breast Reconstruction Surgery

Role: lead

NCT06934889Phase 1Recruiting

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

Role: lead

NCT01603316Phase 2Active Not Recruiting

Food: A Three-Arm Study Examining Food Insecurity Interventions

Role: lead

NCT03473795Active Not Recruiting

Developing Non-Communicable Disease Registries in Africa : A Step Towards Providing Quality Data for Improving Patient Outcomes

Role: lead

NCT07635238Phase 2Recruiting

A Study of Lower Dose Radiation Therapy for People With Prostate Cancer

Role: lead